Selective inhibitors of prostaglandin endoperoxide synthase-2

Details Selective inhibitors of prostaglandin endoperoxide synthase-2 Selective inhibitors of prostaglandin endoperoxide synthase-2

1999-04-06

2001-09-04

Richter, Johann (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C560S135000, C560S138000, C560S142000, C560S145000, C514S546000, C514S554000

Reexamination Certificate

active

06284918

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of molecular pharmacology and the biochemistry of inflammation. More specifically, the present invention relates to a selective 2-acyloxyphenylalkyl, -alkenyl, -alkynyl, and 2-acyloxyphenylaryl sulfide inhibitors of prostaglandin endoperoxide synthase-2.
2. Description of the Related Art
Prostaglandins, particularly prostaglandin E
2
(PGE
2
), are involved in many diverse physiological and pathophysiological functions. These eicosanoids are produced by the action of prostaglandin endoperoxide synthase (PGHS, EC 1.14.99.1) on arachidonic acid. Prostaglandin endoperoxide synthase activity originates from two distinct and independently regulated isozymes, termed as prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 and are encoded by two different genes (1,2).
Prostaglandin endoperoxide synthase-1 is expressed constitutively and is thought to play a physiological role, particularly in platelet aggregation, cytoprotection in the stomach, and regulation of normal kidney function (FIG.
1
). Prostaglandin endoperoxide synthase-2 is the inducible isozyme and expression of prostaglandin endoperoxide synthase-2 is induced by a variety of agents which include endotoxin, cytokines, and mitogens (2,3). Importantly, prostaglandin endoperoxide synthase-2 is induced in vivo to significant levels upon pro-inflammatory stimuli (4).
These discoveries led to the proposal that prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 serve different physiological and pathophysiological functions. For example, the disruption of beneficial prostaglandin production by all of the currently used non-steroidal antiinflammatory drugs (NSAIDs) results in a mechanism-based toxicity mainly in the gastrointestinal tract and kidney and thus limits their therapeutic usefulness especially when long-term treatment is involved (5-7). As a result of this critical finding, a major discovery effort has been excecuted in the pharmaceutical industry to identify selective and orally active prostaglandin endoperoxide synthase-2 inhibitors because they may provide the desired anti-inflammatory and analgesic properties without the deleterious and sometimes life threatening side effects commonly associated with the existing non-steroidal antiinflammatory drugs.
The prior art is deficient in the lack of selective and orally active prostaglandin endoperoxide synthase-2 inhibitors. The present invention fulfills this longstanding need and desire in the art.
SUMMARY OF THE INVENTION
In one embodiment of the present invention, there is provided a compound of the formula
wherein when X is S; R is selected from the group consisting of CH
3
, CH
2
CH
3
, CH
2
Ph, (CH
2
)
2
Ph, (CH
2
)
2
CH
3
, (CH
2
)
3
CH
3
, (CH
2
)
4
CH
3
, (CH
2
)
5
CH
3
, (CH
2
)
6
CH
3
, (CH
2
)
2
O(CH
2
)
3
CH
3
, CH
2
HC═CH(CH
2
)
3
CH
3
, CH
2
C≡C(CH
2
)
3
CH
3
, CH
2
C≡C(CH
2
)
2
CH
3
, CH
2
C≡CCH
2
CH
3
, CH
2
C≡CCH
3
, CH
2
C≡CH, CH
2
C≡C(CH
2
)
4
CH
3
, CH
2
C≡C(CH
2
)
5
CH
3
, CH
2
C≡C(CH
2
)
6
CH
3
, (CH
2
)
2
C≡C(CH
2
)
2
CH
3
, CH(CH
3
)C≡C(CH
2
)
3
CH
3
, (CH
2
)
6
I, (CH
2
)
6
Br, (CH
2
)
5
Br, (CH
2
)
5
COOH and (CH
2
)
5
OCOCH
3
, and R′ is selected from the group consisting of CH
3
, CF
3
, CH
2
Cl, CH
2
Br, CH
2
CH
3
, NH
2
, and OSO
2
CH
3
; wherein when R is CH
3
, R′ can not be CH
3
or CH
2
Cl; wherein when R is CH
2
CH
3
, R′ can not be CH
3
; or a pharmaceutically acceptable salt or hydrate thereof; wherein when X is Se, R is (CH
2
)
6
CH
3
, and R′ is CH
3
or a pharmaceutically acceptable salt or hydrate thereof; and wherein when X is O, R is CH
2
C≡C(CH
2
)
3
CH
3
, and R′ is CH
3
or a pharmaceutically acceptable salt or hydrate thereof.
In another embodiment of the present invention, there is provided a pharmaceutical composition, comprising the novel compounds of the present invention and a pharmaceutically acceptable carrier.
In yet another embodiment of the present invention, there is provided a method of inhibiting the synthesis of prostaglandin endoperoxide syntase-2 (PGHS-2) in a mammal in need of such treatment, comprising the step of administering to said mammal an effective amount of a compound of Formula (I).
Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.


REFERENCES:
patent: 5973191 (1999-10-01), Marnett et al.
Kalgutkar et al., Covalent . . . COX-2 Inactivators, J. Med. Chem., vol. 41, No. 24, pp. 4808-4818, Nov. 1998.

Affiliated with

Also associated with

Rating

Selective inhibitors of prostaglandin endoperoxide synthase-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective inhibitors of prostaglandin endoperoxide synthase-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective inhibitors of prostaglandin endoperoxide synthase-2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2535674